Combining bortezomib to high dose melphalan as conditioning regimen results in the improvement of the response rate in newly diagnosed young multiple myeloma patients

Benedetta Dalla PalmaDepartment of Medicine and Surgery, University of Parma, Parma, Italy; ;Hematology and BMT Unit, “Azienda Ospedaliero-Universitaria di Parma”, Parma, ItalyView further author information

Fabrizio AccardiDepartment of Medicine and Surgery, University of Parma, Parma, Italy; ;Hematology and BMT Unit, “Azienda Ospedaliero-Universitaria di Parma”, Parma, ItalyView further author information

Lucia PreziosoHematology and BMT Unit, “Azienda Ospedaliero-Universitaria di Parma”, Parma, ItalyView further author information

Laura NotarfranchiDepartment of Medicine and Surgery, University of Parma, Parma, Italy; ;Hematology and BMT Unit, “Azienda Ospedaliero-Universitaria di Parma”, Parma, ItalyView further author information

Nicola GiulianiDepartment of Medicine and Surgery, University of Parma, Parma, Italy; ;Hematology and BMT Unit, “Azienda Ospedaliero-Universitaria di Parma”, Parma, ItalyCorrespondence[email protected]

http://orcid.org/0000-0003-3457-3774 View further author information

Click to increase image sizeClick to decrease image size

Acknowledgements

Authors thank the Associazione Italiana contro Leucemie, Linfomi e Mielomi ONLUS, ParmAIL for the support.

Disclosure statement

N. G. received research funding and honoraria from Amgen, Bristol Mayers Squibb, Celgene, Millenium Pharmaceutical, and Janssen Pharmaceutical. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflicts with the subject matter or materials discussed in the manuscript apart from those disclosed.

Additional information

Funding

N. G. received research funding and honoraria from Amgen, Bristol Mayers Squibb, Celgene, Millenium Pharmaceutical, and Janssen Pharmaceutical.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Combining bortezomib to high dose melphalan as conditioning regimen results in the improvement of the response rate in newly diagnosed young multiple myeloma patients

Information for

Open access

Opportunities

Help and information

Combining bortezomib to high dose melphalan as conditioning regimen results in the improvement of the response rate in newly diagnosed young multiple myeloma patients

Acknowledgements

Disclosure statement

Additional information

Funding

Reprints and Corporate Permissions

Academic Permissions

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date

Your download is now in progress and you may close this window

Login or register to access this feature